A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Hoffmann-La Roche
Trishula Therapeutics, Inc.
Servier
Seagen Inc.
Roswell Park Cancer Institute
The Lymphoma Academic Research Organisation
Genentech, Inc.
Progen Pharmaceuticals
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Exelixis
Seagen Inc.
Istituto Clinico Humanitas
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
PharmaMar
Enzon Pharmaceuticals, Inc.